Abrocitinib is a Small Molecule owned by Pfizer, and is involved in 39 clinical trials, of which 28 were completed, 8 are ongoing, and 3 are planned.

Abrocitinib (PF-04965842) is a selective JAK1 inhibitor. Janus kinase (JAKs) binds the cytoplasmic region of trans membrane-cytokine receptors. After receptor-ligand interactions, various JAKs are activated, resulting in tyrosine phosphorylation of the receptor and subsequent activation of STATs (signal transducer and activators of transcription). STATs act as transcription factors. Selective inhibition of JAK1 may block these components and alleviate the condition.

The revenue for Abrocitinib is expected to reach a total of $14bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Abrocitinib NPV Report.

Abrocitinib is originated and owned by Pfizer.

Abrocitinib Overview

Abrocitinib (Cibinqo) is an oral small molecule that selectively acts on Janus kinase (JAK) 1. It is formulated as film coated tablets, tablets for oral route of administration. Cibinqo is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. Cibinqo is indicated for the treatment of atopic dermatitis for which existing treatments are inadequate. Cibinqo is indicated for adult patients with refractory, moderate-to-severe atopic dermatitis who do not respond well to other systemic treatments (such as hormones or biological agents) or who are not suitable for the above treatments.

Abrocitinib (PF-04965842) is under development for the treatment of moderate to severe atopic dermatitis, prurigo nodularis, dermatological disorders and chronic pruritus. It is administered orally as a tablet. The drug candidate acts by targeting janus kinase 1 (JAK1). It was also under development for the treatment of lupus erythematosus and plaque psoriasis. It is a new molecular entity.

Pfizer Overview

Pfizer discovers, develops, manufactures and commercializes biopharmaceuticals. The company offers products to treat various conditions such as cardiovascular, metabolic and pain, cancer, inflammation, immune disorders and rare diseases. It also provides sterile injectable pharmaceuticals, biosimilars, active pharmaceutical ingredients (APIs) and contract manufacturing services. Pfizer sells its products through wholesalers, retailers, hospitals, clinics, government agencies and pharmacies. It has major manufacturing facilities in India, China, Japan, Ireland, Italy, Belgium, Germany, Singapore, and the US. The company provides its products in North America, South America, Asia-Pacific, Australia, Europe, Africa and the Middle East. Pfizer is headquartered in New York, the US.

The company reported revenues of (US Dollars) US$81,288 million for the fiscal year ended December 2021 (FY2021), an increase of 95.2% over FY2020. In FY2021, the company’s operating margin was 29.1%, compared to an operating margin of 18.8% in FY2020. In FY2021, the company recorded a net margin of 27%, compared to a net margin of 22% in FY2020.

Quick View – Abrocitinib

Report Segments
  • Innovator (NME)
Drug Name
  • Abrocitinib
Administration Pathway
  • Oral
Therapeutic Areas
  • Dermatology
  • Immunology
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.